Harmony Biosciences Holdings Inc. has announced an exclusive licensing agreement with Bioprojet Pharma SAS to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin OX2 receptor agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders.